CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
David Baker, Amy MacDougall, Angray S. Kang, View ORCID ProfileKlaus Schmierer, Gavin Giovannoni, Ruth Dobson
doi: https://doi.org/10.1101/2021.09.26.21264023
David Baker
1The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom
Amy MacDougall
2Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom
Angray S. Kang
1The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom
3Centre for Oral Immunobiology and Regenerative Medicine, Dental Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
Klaus Schmierer
1The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom
5Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom
Gavin Giovannoni
1The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom
5Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom
Ruth Dobson
4Preventive Neurology Unit, Wolfson Institute of Population Health, Barts and The London School of Medicine & Dentistry Queen Mary University of London, London, United Kingdom
5Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
All trial data is available via the Vivli.Inc and Clinicalstudydatarequest.com portals which are provided under agreement with the data providers.
Posted September 27, 2021.
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
David Baker, Amy MacDougall, Angray S. Kang, Klaus Schmierer, Gavin Giovannoni, Ruth Dobson
medRxiv 2021.09.26.21264023; doi: https://doi.org/10.1101/2021.09.26.21264023
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
David Baker, Amy MacDougall, Angray S. Kang, Klaus Schmierer, Gavin Giovannoni, Ruth Dobson
medRxiv 2021.09.26.21264023; doi: https://doi.org/10.1101/2021.09.26.21264023
Subject Area
Subject Areas
- Addiction Medicine (347)
- Allergy and Immunology (666)
- Anesthesia (181)
- Cardiovascular Medicine (2637)
- Dermatology (223)
- Emergency Medicine (398)
- Epidemiology (12211)
- Forensic Medicine (10)
- Gastroenterology (758)
- Genetic and Genomic Medicine (4087)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2646)
- Health Policy (1003)
- Hematology (362)
- HIV/AIDS (850)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (433)
- Neurology (3863)
- Nursing (209)
- Nutrition (577)
- Oncology (2022)
- Ophthalmology (584)
- Orthopedics (240)
- Otolaryngology (304)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (472)
- Pediatrics (1113)
- Primary Care Research (450)
- Public and Global Health (6516)
- Radiology and Imaging (1398)
- Respiratory Medicine (871)
- Rheumatology (404)
- Sports Medicine (342)
- Surgery (444)
- Toxicology (52)
- Transplantation (185)
- Urology (165)